Issue Date |
Title |
Author(s) |
2021 |
Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers |
Yang, Xu;Hu, Ying;Yang, Keyan;Wang, Dongxu;Lin, Jianzhen;Long, Junyu;Xie, Fucun;Mao, Jinzhu;Bian, Jin;Guan, Mei;Pan, Jie;Huo, Li;Hu, Ke;Yang, Xiaobo;Mao, Yilei;Sang, Xinting;Zhang, Jiao;Wang, Xi;Zhang, Henghui;Zhao, Haitao |
2018 |
Classification of gallbladder cancer by assessment of CD8(+) TIL and PD-L1 expression |
Lin, Jianzhen;Long, Junyu;Wan, Xueshuai;Chen, Jingci;Bai, Yi;Wang, Anqiang;Yang, Xiaobo;Wu, Yan;Robson, Simon C.;Sang, Xinting;Zhao, Haitao |
2019 |
Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma |
Long, Junyu;Wang, Anqiang;Bai, Yi;Lin, Jianzhen;Yang, Xu;Wang, Dongxu;Yang, Xiaobo;Jiang, Yan;Zhao, Haitao |
9-Dec-2022 |
Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma |
Xie, Fucun;Chen, Bowen;Yang, Xu;Wang, Huaiyuan;Zhang, Ge;Wang, Yanyu;Wang, Yunchao;Zhang, Nan;Xue, Jingnan;Long, Junyu;Li, Yiran;Sun, Huishan;Xun, Ziyu;Liu, Kai;Chen, Xiangqi;Song, Yang;Yang, Xiaobo;Lu, Zhenhui;Mao, Yilei;Sang, Xinting;Lu, Yinying;Zhao, Haitao |
Jul-2020 |
Expression of p42.3 in non-small cell lung cancer |
Zhang, Xinmu;Nie, Xin;Long, Junyu;Yu, Jiangyong;Zhang, Ping;Liu, Yan;Wu, Xiaonan;Bai, Yi;Mao, Jinzhu;Liu, Xiaochuan;Yuan, Yue;Zhao, Haitao;Li, Lin |
6-Aug-2021 |
Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer |
Lin, Jianzhen;Peng, Xinxin;Dong, Kun;Long, Junyu;Guo, Xuejiao;Li, Hongyue;Bai, Yi;Yang, Xu;Wang, Dongxu;Lu, Xin;Mao, Yilei;Sang, Xinting;Ji, Xuwo;Zhao, Haitao;Liang, Han |
21-Jul-2021 |
Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy |
Long, Junyu;Wang, Dongxu;Yang, Xu;Wang, Anqiang;Lin, Yu;Zheng, Mingjun;Zhang, Haohai;Sang, Xinting;Wang, Hanping;Hu, Ke;Zhao, Haitao |
Nov-2021 |
Identification of TMB, CD8 T-cell abundance, and homologous repair pathway mutation frequency as predictors of the benefit-toxicity ratio of anti-PD-1/PD-L1 therapy |
Long, Junyu;Yang, Xu;Bian, Jin;Wang, Dongxu;Wang, Anqiang;Lin, Yu;Zheng, Mingjun;Zhang, Haohai;Sang, Xinting;Zhao, Haitao |
1-Jun-2022 |
Lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma: A large real-world study from two centers. |
Yang, Xu;Chen, Bowen;Wang, Yanyu;Wang, Yunchao;Long, Junyu;Zhang, Nan;Xue, Jinnan;Xun, Ziyu;Zhang, Linzhi;Cheng, Jiamin;Lei, Jin;Pan, Jie;Hu, Ke;Guan, Mei;Huo, Li;Mao, Yilei;Sang, Xinting;Lu, Yinying;Zhao, Hai-Tao |
2021 |
Mutational spectrum and precision oncology for biliary tract carcinoma |
Lin, Jianzhen;Cao, Yinghao;Yang, Xu;Li, Guangyu;Shi, Yang;Wang, Dongxu;Long, Junyu;Song, Yang;Mao, Jinzhu;Xie, Fucun;Bai, Yi;Zhang, Lei;Yang, Xiaobo;Wan, Xueshuai;Wang, Anqiang;Guan, Mei;Zhao, Lin;Hu, Ke;Pan, Jie;Huo, Li;Lu, Xin;Mao, Yilei;Sang, Xinting;Zhang, Henghui;Wang, Kai;Wang, Xiaoyue;Zhao, Haitao |
Aug-2020 |
Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma |
Lin, Jianzhen;Yang, Xu;Long, Junyu;Zhao, Songhui;Mao, Jinzhu;Wang, Dongxu;Bai, Yi;Bian, Jin;Zhang, Lei;Yang, Xiaobo;Wang, Anqiang;Xie, Fucun;Shi, Weiwei;Yang, Huayu;Pan, Jie;Hu, Ke;Guan, Mei;Zhao, Lin;Huo, Li;Mao, Yilei;Sang, Xinting;Wang, Kai;Zhao, Haitao |
2019 |
Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice |
Lin, Jianzhen;Dong, Kun;Bai, Yi;Zhao, Songhui;Dong, Yonghong;Shi, Junping;Shi, Weiwei;Long, Junyu;Yang, Xu;Wang, Dongxu;Yang, Xiaobo;Zhao, Lin;Hu, Ke;Pan, Jie;Sang, Xinting;Wang, Kai;Zhao, Haitao |
2018 |
Prognostic role of neutrophil-to-lymphocyte ratio in unresectable hepatocellular cancer patients treated with trans-arterial chemoembolization |
Xu, Weiyu;Xiong, Jianping;Lin, Jianzhen;Long, Junyu;Bai, Yi;Zheng, Yongchang;Xue, Hongyu;Sang, Xinting;Zhao, Haitao |
Feb-2023 |
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients |
Yang, Xu;Chen, Bowen;Wang, Yanyu;Wang, Yunchao;Long, Junyu;Zhang, Nan;Xue, Jingnan;Xun, Ziyu;Zhang, Linzhi;Cheng, Jiamin;Lei, Jin;Sun, Huishan;Li, Yiran;Lin, Jianzhen;Xie, Fucun;Wang, Dongxu;Pan, Jie;Hu, Ke;Guan, Mei;Huo, Li;Shi, Jie;Yu, Lingxiang;Zhou, Lin;Zhou, Jinxue;Lu, Zhenhui;Yang, Xiaobo;Mao, Yilei;Sang, Xinting;Lu, Yinying;Zhao, Haitao |